0
0
May 12, 2026
A groundbreaking clinical trial from Sweden has found that a slow, low-dose peanut immunotherapy protocol can safely desensitize more than 82% of preschool children with peanut allergies. The study, published May 7, 2026, in The Lancet Regional Health – Europe, represents a major shift toward safer, more accessible allergy management. By utilizing a “gentle” approach to exposure, researchers have opened a new door for the 1.6 million children in the U.S. currently living with this life-threatening condition.
A New Era for Allergy Management
Peanut allergy affects approximately 2.2% of U.S. children and remains a leading cause of food-related anaphylaxis. Historically, the medical gold standard has been strict avoidance—a strategy that mandates constant vigilance and the ever-present shadow of an emergency epinephrine injection.
However, the SMACHO study (Small Children Oral Immunotherapy) has challenged the status quo. Researchers at the Karolinska Institutet in Stockholm demonstrated that “training” the immune system through Oral Immunotherapy (OIT) is not only possible in toddlers but highly effective when done gradually.
The SMACHO Study: Key Findings
The trial involved 75 children aged 1–3 years with confirmed peanut allergies. Participants were divided into two groups: 50 received the low-dose OIT, while 25 followed the traditional avoidance path.
The results after three years were striking:
-
82.5% Success Rate: The vast majority of children in the treatment group could tolerate at least 3.5 peanuts (approximately 600 mg of protein) even after stopping treatment for a full month.
-
High Tolerance: Most children in the treatment group eventually safely consumed up to 25 peanuts.
-
Comparison: In the avoidance group, only 12% of children naturally reached a similar level of tolerance.
“All children who followed the protocol achieved the goal of eating three and a half peanuts without experiencing an allergic reaction,” said Dr. Caroline Nilsson, lead study author and senior consultant at Sachs’ Children and Youth Hospital.
Why “Low and Slow” Matters
The innovation of this study lies in its restraint. Previous OIT trials often utilized aggressive “up-dosing” schedules, which, while effective at building tolerance, frequently triggered the very allergic reactions parents were trying to prevent.
The SMACHO protocol used peanut puffs to deliver tiny, manageable amounts of protein. This “low-dose” strategy—reaching a maintenance level of only about one and a half peanuts per day—was designed to be easier on the child’s system and more sustainable for families.
“This is the first randomised study of oral immunotherapy in toddlers involving a slow up-dosing and a low maintenance dose,” Dr. Nilsson explained. “The peanut puffs were easily ingested, which made the treatment simple for families to follow.”
Comparative Safety Profiles
Safety has always been the primary hurdle for immunotherapy. The SMACHO trial reported a favorable safety profile compared to higher-dose protocols:
| Safety Metric | Findings in SMACHO Study |
| Common Side Effects | Mostly mild (oral itching, skin rashes) |
| Serious Reactions | Rare; primarily occurred during dose-escalation |
| Epinephrine Use | Minimal; required by only a few participants |
| Withdrawal Rate | 0% (No children withdrew due to side effects) |
Critical Warning: Despite these positive results, experts emphasize that OIT is a medical procedure. “This is not something that parents should attempt at home, as serious reactions can still occur,” warned Dr. Anna Asarnoj, co-leader of the study.
The Public Health Context
The psychological and economic burden of peanut allergies is immense. According to the CDC, food allergies have surged in recent decades. Recent data highlights the severity of the issue:
-
59.2% of children with peanut allergies have experienced a severe reaction.
-
50.4% have required at least one emergency department visit.
-
Only 10-20% of children naturally outgrow the allergy.
By intervening during the “preschool window” (ages 1–3), clinicians are taking advantage of a period when the immune system is particularly plastic and receptive to retraining. This aligns with the LEAP study findings, which previously showed that early introduction of peanuts in infancy could reduce allergy development by 80%.
Practical Implications for Families
For parents, this study suggests that the future of allergy treatment may be less “all-or-nothing.” The goal of OIT is often desensitization—providing a “safety buffer” so that an accidental bite of a peanut butter cookie at a birthday party results in a mild itch rather than a trip to the ER.
However, the American Academy of Allergy, Asthma & Immunology (AAAAI) notes that OIT is not a “cure.” Families must still:
-
Carry epinephrine at all times.
-
Read food labels meticulously.
-
Maintain daily dosing to keep the immune system “trained.”
Limitations and Future Outlook
While the SMACHO trial is a landmark, it is not without limitations. The sample size of 75 children is relatively small, and researchers are still investigating how long this tolerance lasts.
Dr. Moshe Ben-Shoshan, a specialist at the Montreal Children’s Hospital, notes that the “best” dose is still a topic of debate. Some studies suggest doses as low as 30mg (a fraction of a peanut) can be effective, while others push for higher amounts to ensure robust protection.
Furthermore, OIT does not work for everyone. Approximately 30–40% of individuals may not respond successfully or may find the side effects too burdensome to continue long-term.
The Road Ahead
The Karolinska Institutet team plans to continue monitoring these children to see if their immune systems remain stable over time. In Sweden, these findings have already influenced national guidelines, with the National Board of Health and Welfare now recommending OIT for children with severe peanut allergies.
As medical science moves toward more personalized, gentle approaches to immunotherapy, the hope is that peanut allergies will transition from a life-threatening “death sentence” to a manageable chronic condition.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://www.ndtv.com/health/low-dose-peanut-therapy-helps-most-allergic-preschoolers-lancet-study-11477985
